348 related articles for article (PubMed ID: 37160786)
21. Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
Tanaka K; Saisho Y; Manesso E; Tanaka M; Meguro S; Irie J; Sugiura H; Kawai T; Jinzaki M; Cobelli C; Itoh H;
Clin Drug Investig; 2015 Oct; 35(10):675-84. PubMed ID: 26369653
[TBL] [Abstract][Full Text] [Related]
22. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
[TBL] [Abstract][Full Text] [Related]
23. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
24. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
Pastel E; McCulloch LJ; Ward R; Joshi S; Gooding KM; Shore AC; Kos K
Clin Sci (Lond); 2017 Mar; 131(5):343-353. PubMed ID: 28049736
[TBL] [Abstract][Full Text] [Related]
25. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
Feng W; Gao C; Bi Y; Wu M; Li P; Shen S; Chen W; Yin T; Zhu D
J Diabetes; 2017 Aug; 9(8):800-809. PubMed ID: 28332301
[TBL] [Abstract][Full Text] [Related]
27. GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.
Iepsen EW; Have CT; Veedfald S; Madsbad S; Holst JJ; Grarup N; Pedersen O; Brandslund I; Holm JC; Hansen T; Torekov SS
Cell Rep Med; 2020 Apr; 1(1):100006. PubMed ID: 33205056
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
[TBL] [Abstract][Full Text] [Related]
29. [Effect of liraglutide in treatment of non-alcoholic fatty liver disease: mechanism of action and research advances].
Liu Y; Feng PP; Zhu W; Gong JP
Zhonghua Gan Zang Bing Za Zhi; 2017 Jun; 25(6):473-476. PubMed ID: 28763870
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease.
Lee HA; Kim HY
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298276
[TBL] [Abstract][Full Text] [Related]
32. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.
He Q; Sha S; Sun L; Zhang J; Dong M
Biochem Biophys Res Commun; 2016 Aug; 476(4):196-203. PubMed ID: 27208776
[TBL] [Abstract][Full Text] [Related]
33. Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice.
Park S; Oh S; Kim EK
J Biol Chem; 2022 Dec; 298(12):102682. PubMed ID: 36356900
[TBL] [Abstract][Full Text] [Related]
34. Liraglutide causes large and rapid epicardial fat reduction.
Iacobellis G; Mohseni M; Bianco SD; Banga PK
Obesity (Silver Spring); 2017 Feb; 25(2):311-316. PubMed ID: 28124506
[TBL] [Abstract][Full Text] [Related]
35. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
Nahra R; Wang T; Gadde KM; Oscarsson J; Stumvoll M; Jermutus L; Hirshberg B; Ambery P
Diabetes Care; 2021 Jun; 44(6):1433-1442. PubMed ID: 34016612
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Zinman B; Gerich J; Buse JB; Lewin A; Schwartz S; Raskin P; Hale PM; Zdravkovic M; Blonde L;
Diabetes Care; 2009 Jul; 32(7):1224-30. PubMed ID: 19289857
[TBL] [Abstract][Full Text] [Related]
37. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
Clemmensen C; Finan B; Fischer K; Tom RZ; Legutko B; Sehrer L; Heine D; Grassl N; Meyer CW; Henderson B; Hofmann SM; Tschöp MH; Van der Ploeg LH; Müller TD
EMBO Mol Med; 2015 Mar; 7(3):288-98. PubMed ID: 25652173
[TBL] [Abstract][Full Text] [Related]
38. [A new era for glucagon-like peptide-1 receptor agonists].
Neuville MF; Paquot N; Scheen AJ
Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
[TBL] [Abstract][Full Text] [Related]
39. Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
Savchenko LG; Digtiar NI; Selikhova LG; Kaidasheva EI; Shlykova OA; Vesnina LE; Kaidashev IP
Rom J Intern Med; 2019 Sep; 57(3):233-240. PubMed ID: 30901315
[TBL] [Abstract][Full Text] [Related]
40. GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
Kadouh H; Chedid V; Halawi H; Burton DD; Clark MM; Khemani D; Vella A; Acosta A; Camilleri M
J Clin Endocrinol Metab; 2020 May; 105(5):1552-63. PubMed ID: 31665455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
